Pre- and postmenopausal women or men with Stage II (Stage IIA limited to max. 1000 patients) or Stage III early invasive breast cancer
Metastatic breast cancer that is measurable (Stage 1) or early breast cancer with a primary tumor size greater than (>) 2 centimeter (cm) (Stage 2)
Unresected operable breast cancer stage II-III with primary tumor > 2.0 cm
Patients must be diagnosed with metastatic cytologically or histologically confirmed adenocarcinoma of the breast with HER2 over-expression or with newly diagnosed locally advanced (including inflammatory) breast cancer (LABC) with stage II-III disease; patients with metastatic (stage IV) disease (MBC) must have measurable lesions
Patients with stage II-III breast cancer are eligible if they are deemed appropriate for neoadjuvant endocrine therapy by the referring or treating medical oncologist. Patients with stage I disease are eligible if they are deemed borderline candidates for breast conservation and the treating surgeon recommends preoperative therapy to increase the chances of breast conservation.
Clinical stage I or II breast cancer for which there will be at least a 2 week period of time between diagnosis and definitive surgery
Clinical stage I-III breast cancer with any invasive residual disease in the breast or axillary nodes following neoadjuvant chemotherapy including HER-2 directed treatment
Early stage (curable) breast cancer
Patients must have a histologically confirmed HER2 positive breast cancer (by immunohistochemistry [IHC] 3+ or fluorescence in situ hybridization [FISH] ratio >= 2.0)\r\n* Phase I: unresectable locally advanced or metastatic breast cancer\r\n* Phase II: clinical stage 2-3 early stage breast cancer
Clinical evidence for a stage T3 or T4 breast cancer
Pathologic or clinical evidence for a stage T4 breast cancer
Newly diagnosed clinical stage II or III ER+/HER2+ breast cancer with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal
a diagnosis of stage I, II, or III breast cancer;
Diagnosed with stage III colon or stage II/III rectal cancer that will receive neoadjuvant or adjuvant chemotherapy but have not yet started
The patient must have clinical node negative, stage I breast cancer
COHORT II: The patient must have clinical node negative, stage I breast cancer
Newly diagnosed clinical stage II or III breast cancer with complete surgical excision of the breast cancer after neoadjuvant chemotherapy as the treatment goal
The patient must have stage 0, I, or II breast cancer; if stage II, the tumor size must be 3 cm or less
New diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as operable Stage I to Stage IIIA breast cancer.
Patients with prior history of stage I-III breast cancer currently without evidence of metastatic disease are eligible if can tolerate further chemotherapy, patients with newly diagnosed synchronous bilateral breast cancers are also eligible if at least one tumor is triple negative (response will be assessed in both breasts if invasive cancer is present in both)
definitively treated, stage I/II ER+ breast cancer
New diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as operable Stage I to Stage IIIA breast cancer.
Subjects with HER-2 expressing stage I – III breast cancer with residual disease in the breast or axillary nodes post-neoadjuvant chemotherapy
History of histologically-confirmed stage 0, I, II, or III breast carcinoma without evidence of disease at trial entry; participants with a resected local recurrence are eligible; site study physicians will review histology from documented pathology reports (which will be recorded in the Inclusion Criteria Case Report Form [CRF]); a separate consent will be obtained for release of medical records to document history of breast cancer diagnosis, staging, and treatment (which will be captured on the Medical History CRF); participants who have a documented history in their medical record of stage 0, I, II, or III breast carcinoma without evidence of disease at trial entry are eligible
Stage III or IV cancer, other than breast cancer, in =< 5 years prior to registration
Subjects with advanced stage breast cancer
Stage II through IIIC HER-2/erbB-2 positive breast cancer with node positive disease.
Histologically confirmed, AJCC stage II or III breast cancer
Histologically confirmed invasive breast carcinoma, with all of the following characteristics: (i) Primary tumor greater than or equal to (>/=) 2 centimeters (cm) in largest diameter (cT1-3) by MRI; (ii) Stage I to operable Stage III breast cancer; (iii) Documented absence of distant metastases (M0)
Relapsed or refractory disease (Stage III or IV): NSCLC or pancreatic cancer must have failed at least 1 prior treatment. Breast cancer must have failed at least 2 prior treatments.
Early stage breast cancer (stage I [tumor size >= 1 cm], II and IIIA)
Past history of treated (newly diagnosed or recurrent) breast, colorectal, prostate, gynecologic (only uterine and cervical) cancers (stage I, II, or III) or any stage lymphoma (Hodgkin’s or non-Hodgkin’s)
Diagnosed with clinical or pathologic stage I?III invasive breast cancer with TX?T3 tumor
Planning to undergo adjuvant or neoadjuvant chemotherapy for stage I-III breast cancer
PHASE I: Diagnosis of stage I to III breast cancer
PHASE II: Diagnosis of stage I to III breast cancer
Histologically confirmed stage I, II or III breast cancer (if the patient has had more than one breast cancer, then the most recent diagnosis)
Survivors with a primary diagnosis of stage I-III breast, ovarian, uterine, or endometrial cancer
Women diagnosed with early stage, resectable breast cancer (Stage 0, I, II, or III) prior to age 45, and are within 5 years of diagnosis
Newly diagnosed and surgically treated females with stage I-III breast cancer
Histologically confirmed diagnosis of early stage breast cancer (stage I-III)
1-3 years post-completion of chemotherapy or/and radiation therapy for stage I-III breast cancer
Women newly diagnosed (stage I-III) breast cancer
Newly diagnosed with stage I-III breast cancer
Diagnosed with stage I, II, or III (a/b) breast cancer
Diagnosed with stage I-III lung cancer
Stage II-III breast cancer
Be diagnosed with breast cancer at stage 0, I, II, III or IV
Women newly diagnosed with stage I to III breast cancer who will be receiving adjuvant or neoadjuvant doxorubicin-based chemotherapy
Diagnosis of stage I to III breast cancer
Diagnosed with any stage breast, GI, or lung cancer
Patients with stage I-III breast cancer
Diagnosed with stage 0, I, II, or IIIa breast cancer, confirmed by medical record
Participants must self-identify as having a medical history of histologically confirmed stage 0, I, II, III breast cancer, or I with no evidence of metastatic disease
Have a history of stage I, II, or III breast cancer
Patients must have evidence of histologically confirmed invasive breast cancer, stage I, II or III, and be at least 2 years post diagnosis
Diagnosed with stage 0-III hormone-receptor positive breast cancer (BCa)
Histologically or cytologically confirmed, stage I-III breast cancer
Diagnosed with early stage (I-III) breast cancer, without evidence of metastatic disease
Prior diagnosis of stage 0 to stage III breast cancer
Have a diagnosis of breast cancer (BC) (stage I-III)
Have breast cancer stage 0-IIIA
Women with stage II or III breast cancer that will be scheduled to undergo a 4 to 6-week course of radiotherapy
Has been diagnosed with early-stage breast cancer
Breast cancer stage I-III
Histologic or cytologic proven breast cancer or colon cancer (stage I, II or III)
Women previously diagnosed with stage 0-IIIA breast cancer
Histologically confirmed stage I, II or III breast cancer (if the patient has had more than one breast cancer, then the most recent diagnosis)
Patients with early-stage breast cancer (stage I-III)
Have been diagnosed with stage 0-III breast cancer; bilateral or multiple primary breast cancers are permitted
In early survivorship phase, defined as being 1-12 months post completion of treatment for stage 0-3 breast cancer
PHASE II: Has a first, primary diagnosis of unilateral stage 0, 1, 2, or 3a breast cancer
Diagnosed with stage 0-III breast cancer within the past 3 years
A diagnosis of breast cancer, stage I, II, or III
Women with stage 1-3 breast cancer who are within first two rounds of chemotherapy OR women who have stage 4 breast cancer at initial diagnosis and are initiating first line chemotherapy; note: women with stage 4 breast cancer must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Stage I-III gynecologic cancer (any site) or breast cancer
Women with stage 0-III breast cancer who will be undergoing daily adjuvant radiation for 4-6 weeks (patients only)
History of histologically or cytologically proven stage I-III breast cancer receiving intravenous chemotherapy on an every 14 days or every 21 days schedule
History of stage 0-III breast cancer
Diagnosed with stage I-II endometrial cancer
Has diagnosis of non-recurrent stage I-III breast cancer
Women with a history of cancer, any stage, with breast or gynecologic cancer
Are diagnosed with primary breast cancer (BC) (stages I-III)
SCREENING PHASE: Histologically proven stage I-III carcinoma of the breast
INTERVENTION PHASE: Histologically proven stage I-III carcinoma of the breast
Stage 0-IIIA breast cancer survivors and their partner
History of stage 0-III breast cancer or stage I-III ovarian cancer; all antitumor therapies, excluding hormonal therapy, have been completed at least 60 days prior to enrollment
Subjects with newly diagnosed stage I (T > 1 cm), II or III TNBC who have not undergone definitive breast surgery and have not received systemic chemotherapy will be eligible
Stage I and II breast cancer patients undergoing active radiation therapy
Diagnosis of stage 0 to III breast cancer
Newly diagnosed breast cancer (stage I, II, III)
Newly diagnosed with stage I-III breast cancer
Stage 0-III invasive carcinoma of the breast
Diagnosis of stage I, II, or III ovarian cancer
Patients with stage 0-III breast cancer, status-post surgery treated with standard chemotherapy/chemoprevention and/or radiation
History of stage I-III breast, gastrointestinal or gynecologic cancer
Diagnosed with stage I-III cancer other than cancers of the brain or spinal cord (confirmed by patient self-report on the Health History Questionnaire; if patient is unable to confirm either the site of her cancer or that her stage of cancer is < stage IV, we will send a letter to her physician to confirm this criterion)
2) Patients must have a diagnosis of breast cancer for which they must not have received or been scheduled for primary breast surgery at time of project intervention, and must be eligible for surgical resection (i.e. Stage I-III).
Stage I-III female breast cancer (including inflammatory and newly diagnosed, or locally recurrent but not metastatic breast cancer being treated with curative intent)
AJCC stage I - III non-inflammatory, HER2-positive (according to ASCO-CAP guidelines 5) breast cancer
Eligibility criteria will include: Postmenopausal women with of first incidence of early stage (stages 0 - III) hormone receptor positive breast cancer stabilized on anastrozole therapy for at least 3 months
Stage I-III breast cancer (including inflammatory and newly diagnosed recurrent breast cancer) or lymphoma stage I-IV; (patients should have a > 2 year life expectancy)
The patient can undergo biopsy or surgery of a primary tumor site for suspected or proven invasive breast cancer of clinical stage I to III
History of stage I-III breast cancer
Breast cancer (any stage)
Participants who are breast cancer free (mammogram “negative” within 1 month of testing) with the absence of clinical suspicion of breast cancer on physical exam or with stage II or stage III breast cancer will be invited to participate in the study
Patients without known bone metastases who are newly diagnosed with ? stage 3 breast cancer, ? stage 3 lung cancer, or ? stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer
Women with stage I-III breast cancer who began their cancer treatment 1-2 years prior to this study and have received anthracycline based chemotherapy
A new diagnosis of invasive breast cancer > 1.0 cm in size, ER+ clinical stage I-III
The patient is diagnosed with non-invasive breast cancer, benign breast disease, or other than stage II or stage III invasive breast cancer
Stage 4 breast cancer
First diagnosis with stage 1-2 breast or stage 1-2 lung cancer; and voluntary participation
AND diagnosed with Stage I-III incident breast or colorectal cancers;
